Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603040 | 0.86 | SIGMAR1 (0.46) | SIGMAR1OPRM1 | |
| SCHEMBL6602829 | 0.84 | OPRM1 (0.47) | OPRM1 | |
| SCHEMBL6603218 | 0.81 | DRD2 (0.47) | DRD3SIGMAR1OPRM1 | |
| SCHEMBL6607339 | 0.79 | DRD3 (0.42) | DRD3SIGMAR1OPRM1 | |
| SCHEMBL6655150 | 0.75 | DRD3 (0.69) | DRD3OPRM1 | |
| SCHEMBL6655519 | 0.75 | DRD3 (0.50) | DRD3SIGMAR1OPRM1 | |
| SCHEMBL6658680 | 0.69 | OPRM1 (0.46) | DRD3SIGMAR1OPRM1 | |
| SCHEMBL6654627 | 0.69 | OPRM1 (0.51) | DRD3OPRM1 | |
| SCHEMBL6657899 | 0.69 | DRD3 (0.47) | DRD3OPRM1 | |
| SCHEMBL6656866 | 0.69 | DRD3 (0.47) | DRD3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1072601-B1 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6750231-B2 | SKIN DISORDERS; GASTROINTESTINAL DISORDERS | PFIZER INC | 2004-06-15 | — | — | US | disclosed |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | GIBSON STEPHEN PAUL (GB) | 2003-01-02 | — | — | US | disclosed |
| EP-1072601-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | HRH2, HRH4, HRH1 | DRD3 136/4885SIGMAR1 51/4885OPRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.